Input Form
Complete all sections for the most accurate biologic recommendation.
Condition
Select the primary diagnosis
Patient profile
Demographics and baseline characteristics
Relevant for ustekinumab, some biologics
Disease characteristics
Current disease burden and distribution
Comorbidities
Select all that apply — these directly affect biologic choice
✓
Psoriatic arthritis
Favors IL-17 / IL-23 agents
✓
Inflammatory bowel disease
Critical — affects IL-17 eligibility
✓
Cardiovascular disease
Favors IL-23 inhibitors
✓
Allergic asthma
Favors dupilumab (if AD)
✓
Recurrent serious infections
Caution with all biologics
✓
Demyelinating disease
Contraindicates TNF inhibitors
✓
Diabetes
Consider monitoring requirements
✓
Obesity (BMI >30)
Affects ustekinumab efficacy
✓
Pregnancy / planning pregnancy
Significantly affects biologic choice
✓
Prior or active malignancy
Caution with some agents
✓
Hepatitis B (active or prior)
Antiviral prophylaxis required
✓
TB exposure / latent TB
Must be treated before TNF inhibitors
Pregnancy status
Note: Certolizumab (Cimzia) is the preferred TNF inhibitor in pregnancy — does not cross placenta. For AD, dupilumab has the most reassuring registry data.
Treatment history
Prior and current treatments
Add each biologic tried — drug and reason for stopping
Practical factors
Access, preference, and adherence considerations
Oral options exist for some conditions (JAK inhibitors, TYK2 inhibitor)
Applicable options
Updates live as you complete the form
Complete the form above — applicable biologics will appear here as you make selections.
Complete the form above to generate a personalized biologic recommendation with contraindication alerts.
Not a substitute for clinical judgment or institutional prescribing guidelines.